DDInter1095 DDInter1376
Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide]. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Losartan {u} (Compound) resembles {v} (Compound) Candesartan
Losartan {u} (Compound) resembles {v} (Compound) Eprosartan
Losartan {u} (Compound) treats {v} (Disease) coronary artery disease
Losartan {u} (Compound) binds {v} (Gene) UGT2B7
Losartan {u} (Compound) upregulates {v} (Gene) RRS1
Losartan {u} (Compound) is included by {v} (Pharmacologic Class) Angiotensin 2 Receptor Antagonists
Losartan {u} (Compound) downregulates {v} (Gene) GNAS
Losartan {u} (Compound) causes {v} (Side Effect) Cataract
Losartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludrocortisone
Losartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Losartan (Compound) resembles Candesartan (Compound)
Losartan (Compound) resembles Eprosartan (Compound)
Losartan (Compound) treats coronary artery disease (Disease)
Losartan (Compound) binds UGT2B7 (Gene)
Losartan (Compound) upregulates RRS1 (Gene)
Losartan (Compound) is included by Angiotensin 2 Receptor Antagonists (Pharmacologic Class)
Losartan (Compound) downregulates GNAS (Gene)
Losartan (Compound) causes Cataract (Side Effect)
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine